title: Advances in the understanding of the Fanconi anemia tumor suppressor pathway.
abstract: Extremely high cancer incidence in Fanconi anemia (FA) patients has long suggested that the FA signaling pathway is a tumor suppressor pathway. Indeed, our recent findings, for the first time, indicate that the FA pathway plays a significant role in suppressing the development of non-FA human cancer. Also our studies on FA group D2 protein (FANCD2) have, among the first, documented the crosstalks between the FA and Rad6/Rad18 (HHR6) pathways upon DNA damage. In this review, we will discuss how our studies enhance the understanding of the FA tumor suppressor pathway.
authors.affiliation: University of Hawaii Cancer Center; University of Hawaii; Honolulu, HI USA.
authors.forename: Anna
authors.initials: A
authors.lastname: Pickering
authors.affiliation: Department of Laboratory Medicine and Pathology; Mayo Clinic; Rochester, MN USA.
authors.forename: Jun
authors.initials: J
authors.lastname: Zhang
authors.affiliation: University of Hawaii Cancer Center; University of Hawaii; Honolulu, HI USA.
authors.forename: Jayabal
authors.initials: J
authors.lastname: Panneerselvam
authors.affiliation: University of Hawaii Cancer Center; University of Hawaii; Honolulu, HI USA.
authors.forename: Peiwen
authors.initials: P
authors.lastname: Fei
mesh_terms: D000818:Animals; D004249:DNA Damage; D005199:Fanconi Anemia / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D052236:Fanconi Anemia Complementation Group D2 Protein / Q000235:genetics / Q000378:metabolism; D016147:Genes, Tumor Suppressor; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000378:metabolism / Q000473:pathology; D015398:Signal Transduction; D054875:Ubiquitination
chemical_list: D052236:Fanconi Anemia Complementation Group D2 Protein
keywords: DNA damage; DNA polymerase eta; Rad6/Rad18 pathway; non-FA human tumors; the FA tumor suppressor pathway; translesion synthesis
references.citation: Oncotarget. 2013 Sep;4(9):1416-26
references.pmid: 23965832
references.citation: Nat Genet. 2007 Feb;39(2):159-61
references.pmid: 17200672
references.citation: Curr Opin Hematol. 2003 Jan;10(1):68-76
references.pmid: 12483114
references.citation: Blood. 2006 Jun 1;107(11):4223-33
references.pmid: 16493006
references.citation: Cancer Cell. 2005 Sep;8(3):255-65
references.pmid: 16153896
references.citation: Nat Rev Genet. 2007 Oct;8(10):735-48
references.pmid: 17768402
references.citation: Cell Cycle. 2012 Aug 1;11(15):2947-55
references.pmid: 22828653
references.citation: Cell Cycle. 2008 Feb 1;7(3):407-13
references.pmid: 18277096
references.citation: Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3
references.pmid: 5279523
references.citation: PLoS One. 2010 Oct 13;5(10):e13313
references.pmid: 20967207
references.citation: Mol Cell Biol. 2004 Jun;24(12):5485-95
references.pmid: 15169909
references.citation: Nat Genet. 2007 Feb;39(2):165-7
references.pmid: 17200668
references.citation: J Natl Cancer Inst. 2003 Feb 5;95(3):214-21
references.pmid: 12569143
references.citation: Mol Cell. 2004 May 21;14(4):491-500
references.pmid: 15149598
references.citation: Science. 2002 Jul 26;297(5581):606-9
references.pmid: 12065746
references.citation: Cell Cycle. 2013 May 15;12(10):1625-36
references.pmid: 23624835
references.citation: J Cell Biol. 2010 Oct 18;191(2):249-57
references.pmid: 20937699
references.citation: Cell Cycle. 2012 Nov 1;11(21):3983-96
references.pmid: 22987153
references.citation: Leukemia. 2004 Mar;18(3):420-5
references.pmid: 14749703
references.citation: Am J Hum Genet. 2013 May 2;92(5):800-6
references.pmid: 23623386
references.citation: Oncogene. 2004 Jan 29;23(4):1000-4
references.pmid: 14647419
references.citation: Nat Rev Cancer. 2003 Jan;3(1):23-34
references.pmid: 12509764
references.citation: Nat Genet. 2005 Sep;37(9):958-63
references.pmid: 16116422
references.citation: Genes Dev. 2003 Aug 15;17(16):1933-6
references.pmid: 12893780
references.citation: Exp Cell Res. 2000 Nov 1;260(2):208-15
references.pmid: 11035915
references.citation: Mol Cell. 2006 Jun 23;22(6):719-729
references.pmid: 16793542
references.citation: Nat Med. 2003 May;9(5):568-74
references.pmid: 12692539
references.citation: Cancer Biol Ther. 2006 Dec;5(12):1632-6
references.pmid: 17106252
references.citation: Breast Cancer Res Treat. 2008 Jan;107(1):41-7
references.pmid: 17333336
references.citation: Cell Cycle. 2013 Mar 1;12(5):803-9
references.pmid: 23388460
references.citation: J Clin Invest. 2010 May;120(5):1524-34
references.pmid: 20407210
references.citation: Nat Genet. 2007 Feb;39(2):162-4
references.pmid: 17200671
references.citation: Mol Cell. 2003 Jan;11(1):261-6
references.pmid: 12535538
references.citation: Cancer Res. 2004 May 1;64(9):2994-7
references.pmid: 15126331
references.citation: Nat Cell Biol. 2006 Apr;8(4):339-47
references.pmid: 16531995
references.citation: Nat Rev Cancer. 2011 Jun 24;11(7):467-80
references.pmid: 21701511
references.citation: Nature. 1971 Apr 9;230(5293):370-3
references.pmid: 4927726
references.citation: Cell Cycle. 2005 Jan;4(1):80-6
references.pmid: 15611632
references.citation: Science. 2005 Dec 16;310(5755):1821-4
references.pmid: 16357261
references.citation: Nat Genet. 2005 Sep;37(9):934-5
references.pmid: 16116423
references.citation: J Biol Chem. 2010 Oct 8;285(41):31525-36
references.pmid: 20675655